Axsome Therapeutics (AXSM) is back in focus after detailing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by a larger sales force and expectations of broad Medicare Part D coverage.

The June AUVELITY launch plan for Alzheimer’s agitation and recent first quarter 2026 earnings have arrived alongside strong momentum, with a 30 day share price return of 26.11% and a one year total shareholder return of 116.63%.

If this kind of central nervous system focus has your attention, it could be worth seeing what else is moving in healthcare related AI by checking out 34 healthcare AI stocks

With the stock up sharply over the past year and trading at about a 16% discount to the average analyst price target, the real question is whether Axsome is still undervalued or if the market already reflects its future growth.

Most Popular Narrative: 13% Undervalued

Axsome’s most followed valuation narrative puts fair value at $266.94 versus the last close of $232.27, suggesting the market may not fully reflect its CNS ambitions yet.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications). This positions Axsome to potentially benefit from the aging population and the rising prevalence of CNS disorders, which could result in a more diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

Investors may be curious about what kind of revenue ramp, margin expansion and future earnings multiple are implied in that fair value estimate, and how much growth each late-stage asset contributes to the model.

Result: Fair Value of $266.94 (UNDERVALUED)

However, you still need to weigh execution and financing risks, as continued net losses and high R&D and commercial spending leave room for earnings or funding setbacks.

Another View: Rich Sales Multiple Raises the Bar

That 13% undervalued narrative sits alongside a very different signal from the market price. Axsome trades on a P/S of 16.9x, compared with 5.4x for the US Pharmaceuticals industry, a peer average of 7.4x, and an estimated fair ratio of 15.7x.

In plain terms, investors are already paying a sizeable premium to industry and peers, and even a bit above the fair ratio that the market could move towards. This adds valuation risk if growth or margins fall short of expectations. The question is whether you think Axsome can grow into that premium or not.

Next Steps

If this mixed picture leaves you uncertain, use it as a prompt to look at the numbers yourself and decide where you stand. To see what is driving investor optimism in the current narrative, start by reviewing the 2 key rewards

Looking for more investment ideas?

If Axsome has sharpened your curiosity, do not stop here. Broaden your watchlist with other potential opportunities that fit different goals and risk profiles.

• Target potential mispricings by scanning for companies that combine quality fundamentals with appealing valuations through the 47 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that offer higher yields and resilient payouts via the 13 dividend fortresses.
• Prioritise resilience by checking companies that score well on balance sheet strength and fundamentals using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.